• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Senti Biosciences, Inc. (SNTI) Stock Price, News & Analysis

Senti Biosciences, Inc. (SNTI) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.17

-$0.02

(-0.88%)

Day's range
$2.11
Day's range
$2.22
50-day range
$2
Day's range
$3.29
  • Country: US
  • ISIN: US81726A1007
52 wk range
$1.52
Day's range
$7.43
  • CEO: Dr. Timothy K. Lu M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -10.49
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (SNTI)
  • Company Senti Biosciences, Inc.
  • Price $2.17
  • Changes Percentage (-0.88%)
  • Change -$0.02
  • Day Low $2.11
  • Day High $2.22
  • Year High $7.43

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.83
  • Trailing P/E Ratio -0.15
  • Forward P/E Ratio -0.15
  • P/E Growth -0.15
  • Net Income $-92,919,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Senti Biosciences, Inc. Frequently Asked Questions

  • What is the Senti Biosciences, Inc. stock price today?

    Today's price of Senti Biosciences, Inc. is $2.17 — it has decreased by -0.88% in the past 24 hours. Watch Senti Biosciences, Inc. stock price performance more closely on the chart.

  • Does Senti Biosciences, Inc. release reports?

    Yes, you can track Senti Biosciences, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Senti Biosciences, Inc. stock forecast?

    Watch the Senti Biosciences, Inc. chart and read a more detailed Senti Biosciences, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Senti Biosciences, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Senti Biosciences, Inc. stock ticker.

  • How to buy Senti Biosciences, Inc. stocks?

    Like other stocks, SNTI shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Senti Biosciences, Inc.'s EBITDA?

    Senti Biosciences, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Senti Biosciences, Inc.’s financial statements.

  • What is the Senti Biosciences, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -36.282311597, which equates to approximately -3,628.23%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Senti Biosciences, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Senti Biosciences, Inc.'s financials relevant news, and technical analysis. Senti Biosciences, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Senti Biosciences, Inc. stock currently indicates a “sell” signal. For more insights, review Senti Biosciences, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.